Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens Sells 341 Shares

Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $61.24, for a total transaction of $20,882.84. Following the transaction, the chief accounting officer now directly owns 63,239 shares of the company’s stock, valued at approximately $3,872,756.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Andrea Sabens also recently made the following trade(s):

• On Tuesday, February 13th, Andrea Sabens sold 341 shares of Lantheus stock. The shares were sold at an average price of $55.31, for a total transaction of $18,860.71.

Lantheus Trading Down 0.4 %

NASDAQ LNTH traded down $0.25 during trading on Wednesday, hitting $61.48. The stock had a trading volume of 536,995 shares, compared to its average volume of 1,059,682. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The stock has a market capitalization of $4.21 billion, a price-to-earnings ratio of 13.48 and a beta of 0.53. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $100.85. The stock has a 50 day simple moving average of $60.39 and a 200 day simple moving average of $63.01.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Sell-side analysts predict that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Truist Financial reissued a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a report on Monday, February 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd. B. Riley lowered their price target on shares of Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a report on Wednesday, January 10th. Finally, StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $104.14.

Institutional Trading of Lantheus

Institutional investors have recently added to or reduced their stakes in the company. Tucker Asset Management LLC lifted its stake in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the last quarter. Principal Securities Inc. bought a new stake in Lantheus in the fourth quarter worth about $28,000. First Horizon Advisors Inc. lifted its stake in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 225 shares during the last quarter. West Tower Group LLC lifted its stake in Lantheus by 534.1% in the fourth quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 438 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its position in shares of Lantheus by 60.2% during the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 160 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.